Bioanalysis of Ibrutinib and its Active Metabolite in Human Plasma: Selectivity Issue, Impact Assessment and Resolution
Authors:
- 28 October 2015
- journal article
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (20) , 2713-2724
Abstract
Ronald de Vries graduated in Organic and Analytical Chemistry at the Free University of Amsterdam, The Netherlands. After working in a Contract Laboratory (CRO) for 7 years, he joined Janssen R&D in 1998. At Janssen R&D, Belgium, Ronald worked in the bioanalytical department that supports both clinical and nonclinical bioanalysis. In this department he had several roles, such as providing the bioanalytical support for various drug development programs and leading the method establishment group. He has done numerous global assay transfers to/from Janssen from/to other laboratories and plays an important role in the introduction and application of new technologies and applied innovation in the department. In 2014 he started in the drug metabolism and pharmacokinetics department of Janssen R&D, where his main tasks are in vivo and in vitro metabolite identification using high resolution MS and Radiodetection. Ibrutinib is a potent, covalently binding inhibitor of Bruton's tyrosine kinase. Quantitative LC-MS/MS methods for ibrutinib and metabolite dihydrodiol-ibrutinib in human plasma were validated in the range 0.500–100 ng/ml. Selectivity of the assay toward isobaric metabolites and endogenous compounds was optimized and incurred sample reproducibility and stability were assessed. During analysis of plasma samples from a clinical study in hepatically impaired subjects, bile acids, more specifically taurocholic acid, showed interference with the internal standard of dihydrodiol-ibrutinib. This interference was significant in samples from hepatically impaired subjects, but did not impact results from all other clinical studies analyzed. The method was modified and revalidated, and an impact assessment was performed. The original method and the modified method were cross-validated.Keywords
This publication has 20 references indexed in Scilit:
- Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy MenDrug Metabolism and Disposition, 2015
- Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array DetectionJournal of Analytical Methods in Chemistry, 2015
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyThe Lancet Oncology, 2014
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Ibrutinib in chronic lymphocytic leukemia and B cell malignanciesLeukemia & Lymphoma, 2013
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesJournal of Clinical Oncology, 2013
- PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignanciesExpert Opinion on Investigational Drugs, 2012
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010